The stock of Recro Pharma Inc (NASDAQ:REPH) is a huge mover today! About 1.36 million shares traded hands or 1770.75% up from the average. Recro Pharma Inc (NASDAQ:REPH) has risen 9.45% since April 25, 2016 and is uptrending. It has outperformed by 3.44% the S&P500.
The move comes after 5 months positive chart setup for the $116.60 million company. It was reported on Nov, 28 by Barchart.com. We have $10.56 PT which if reached, will make NASDAQ:REPH worth $8.16M more.
Analysts await Recro Pharma Inc (NASDAQ:REPH) to report earnings on March, 23. They expect $-0.90 earnings per share, down 157.14% or $0.55 from last year’s $-0.35 per share. After $-0.50 actual earnings per share reported by Recro Pharma Inc for the previous quarter, Wall Street now forecasts 80.00% negative EPS growth.
Recro Pharma Inc (NASDAQ:REPH) Ratings Coverage
Out of 6 analysts covering Recro Pharma (NASDAQ:REPH), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Recro Pharma has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, November 14 by Aegis Capital. The firm earned “Buy” rating on Friday, September 16 by TH Capital. The company was upgraded on Tuesday, August 25 by Zacks. The firm earned “Buy” rating on Monday, October 3 by Brean Capital. Roth Capital initiated the stock with “Buy” rating in Friday, September 16 report. The stock has “Buy” rating given by Janney Capital on Monday, August 29. H.C. Wainwright initiated Recro Pharma Inc (NASDAQ:REPH) rating on Wednesday, September 2. H.C. Wainwright has “Buy” rating and $19 price target. The stock has “Buy” rating given by H.C. Wainwright on Tuesday, November 24.
According to Zacks Investment Research, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.”
Insitutional Activity: The institutional sentiment increased to 2.22 in 2016 Q2. Its up 0.42, from 1.8 in 2016Q1. The ratio is positive, as 1 funds sold all Recro Pharma Inc shares owned while 4 reduced positions. 4 funds bought stakes while 5 increased positions. They now own 3.87 million shares or 0.55% less from 3.89 million shares in 2016Q1.
Blackrock Advisors Limited Liability Corporation accumulated 1,103 shares or 0% of the stock. Blackrock Institutional Trust Na holds 49,947 shares or 0% of its portfolio. Blackrock Inv Management Limited Co owns 1,073 shares or 0% of their US portfolio. Morgan Stanley owns 7,724 shares or 0% of their US portfolio. Globeflex Lp last reported 101 shares in the company. Manufacturers Life Ins Com The, a Ontario – Canada-based fund reported 814 shares. Vanguard Incorporated holds 0% of its portfolio in Recro Pharma Inc (NASDAQ:REPH) for 107,252 shares. Blackrock Fund Advsrs has 0% invested in the company for 15,268 shares. National Bank Of America Corp De has 0% invested in the company for 55 shares. Walleye Trading Limited Com last reported 1,500 shares in the company. Cormorant Asset Management Limited Co has 778,288 shares for 0.88% of their US portfolio. Tower Research Capital Lc (Trc) holds 0% or 180 shares in its portfolio. Geode Mgmt Ltd Liability Com has 0% invested in the company for 25,775 shares. Moreover, Tourbillon Capital Prns Ltd Partnership has 0.1% invested in Recro Pharma Inc (NASDAQ:REPH) for 646,552 shares. Wells Fargo & Commerce Mn holds 20,000 shares or 0% of its portfolio.
Insider Transactions: Since May 31, 2016, the stock had 1 buy, and 0 sales for $2.93 million net activity. Shares for $2.93 million were bought by Broadfin Healthcare Master Fund Ltd on Tuesday, August 16. Graff Fred bought $67,707 worth of Recro Pharma Inc (NASDAQ:REPH) on Tuesday, May 31.
More news for Recro Pharma Inc (NASDAQ:REPH) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on March 10, 2014. Streetinsider.com‘s article titled: “Recro Pharma (REPH) Announces IV Meloxicam Phase 3 Met Primary Endpoint” and published on November 28, 2016 is yet another important article.
REPH Company Profile
Recro Pharma, Inc., incorporated on November 15, 2007, is a clinical-stage specialty pharmaceutical company. The Firm is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. The Company’s product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. The Company’s manufacturing and development capabilities include formulation through process development, scale-up and full-scale commercial manufacturing and specialized capabilities for the development and manufacturing of controlled substances.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.